VIRI Dogwood Therapeutics Inc.


$ 6.24 $ 0.43 (7.47 %)    

Monday, 20-Oct-2025 17:45:16 EDT
QQQ $ 611.72 $ 7.61 (1.26 %)
DIA $ 467.26 $ 5.24 (1.13 %)
SPY $ 671.65 $ 6.91 (1.04 %)
TLT $ 91.59 $ 0.35 (0.38 %)
GLD $ 401.50 $ 14.16 (3.64 %)
$ 6.19
$ 5.86
$ 5.84 x 300
$ 6.30 x 8
$ 5.76 - $ 6.26
$ 1.62 - $ 29.28
55,344
na
na
$ 2.26
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-neutral-on-virios-therapeutics-adjusts-price-target-to-5-25-1-reverse-stock-split

HC Wainwright & Co. analyst Sean Lee maintains Virios Therapeutics (NASDAQ:VIRI) with a Neutral, adjusts target to $5 from ...

Core News & Articles

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), and Wex Pharmaceuticals, Inc. ("WEX"), a wholly owned ...

 hc-wainwright--co-maintains-neutral-on-virios-therapeutics-lowers-price-target-to-02

HC Wainwright & Co. analyst Sean Lee maintains Virios Therapeutics (NASDAQ:VIRI) with a Neutral and lowers the price tar...

 virios-therapeutics-q2-2024-gaap-eps-005-inline

Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This...

 maxim-group-initiates-coverage-on-virios-therapeutics-with-buy-rating-announces-price-target-of-1

Maxim Group analyst Jason McCarthy initiates coverage on Virios Therapeutics (NASDAQ:VIRI) with a Buy rating and announces P...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION